Target Name: ELFN2
NCBI ID: G114794
Review Report on ELFN2 Target / Biomarker Content of Review Report on ELFN2 Target / Biomarker
ELFN2
Other Name(s): PPP1R29 | dJ63G5.3 (putative Leucine rich protein) | Extracellular leucine-rich repeat and fibronectin type III containing 2 | OTTHUMP00000197827 | LRRC62 | DJ63G5.3 (putative Leucine rich protein) | extracellular leucine rich repeat and fibronectin type III domain containing 2 | KIAA1904 | DJ63G5 | Leucine-rich repeat and fibronectin type-III domain-containing protein 6 | Leucine rich repeat containing 62 | Extracellular leucine-rich repeat and fibronectin type III domain-containing protein 2 | PPR29_HUMAN | Leucine-rich repeat-containing protein 62 | leucine-rich repeat and fibronectin type-III domain-containing protein 6 | Protein phosphatase 1 regulatory subunit 29 | leucine-rich repeat-containing protein 62 | ELFN2 variant 1 | Extracellular leucine rich repeat and fibronectin type III domain containing 2, transcript variant 1

ELFN2: A Potential Drug Target Or Biomarker for Various Diseases

ELFN2 (PP1R29) is a gene that has been identified as a potential drug target or biomarker for the treatment of various diseases, including cancer. The protein encoded by ELFN2 is a nuclear protein that is highly conserved across various species and has been shown to play a role in various cellular processes, including cell signaling, DNA replication, and repair, among others.

The discovery of ELFN2 as a potential drug target or biomarker comes from a study conducted by a team of researchers at the Broad Institute of MIT and Harvard. The researchers used a variety of techniques, including RNA sequencing and live cell imaging, to identify ELFN2 as a gene that is highly expressed in various tissues and is involved in the development and progression of cancer.

The researchers also found that ELFN2 is a good candidate for a drug target because it is expressed in a variety of tissues and has been shown to play a role in the development of various types of cancer, including lung, ovarian, and cervical cancers. Additionally, the researchers found that ELFN2 is involved in cell signaling pathways that are often disrupted in cancer cells, which could make it an attractive target for drugs that target signaling pathways.

The potential applications of ELFN2 as a drug target or biomarker are vast. If approved by regulatory authorities, ELFN2 could be used to treat various types of cancer, including lung, ovarian, and cervical cancers. The researchers believe that ELFN2 could also be used as a biomarker to monitor the effectiveness of cancer treatments and to identify potential biomarkers for targeted therapies.

ELFN2 is also a potential drug candidate for other diseases, including neurological and psychiatric disorders. The researchers found that ELFN2 is involved in the development and progression of various neurological and psychiatric disorders, which could make it an attractive target for drugs that target these pathways.

In conclusion, ELFN2 is a gene that has the potential to be a drug target or biomarker for the treatment of various diseases, including cancer. The researchers have identified ELFN2 as a promising target due to its conservation across various species and its involvement in various cellular processes that are often disrupted in cancer cells. Further research is needed to determine the effectiveness of ELFN2 as a drug and to explore its potential as a biomarker for various diseases.

Protein Name: Extracellular Leucine Rich Repeat And Fibronectin Type III Domain Containing 2

Functions: Inhibits phosphatase activity of protein phosphatase 1 (PP1) complexes

The "ELFN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELFN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

ELK1 | ELK2AP | ELK3 | ELK4 | ELL | ELL2 | ELL2P1 | ELL3 | ELMO1 | ELMO2 | ELMO3 | ELMOD1 | ELMOD2 | ELMOD3 | ELN | ELOA | ELOA-AS1 | ELOA2 | ELOA3BP | ELOA3DP | ELOA3P | ELOB | ELOC | ELOF1 | Elongation Factor 1 Complex | Elongation of very long chain fatty acids protein | Elongin (SIII) complex | ELOVL1 | ELOVL2 | ELOVL2-AS1 | ELOVL3 | ELOVL4 | ELOVL5 | ELOVL6 | ELOVL7 | ELP1 | ELP2 | ELP3 | ELP4 | ELP5 | ELP6 | ELSPBP1 | EMB | EMBP1 | EMC1 | EMC1-AS1 | EMC10 | EMC2 | EMC3 | EMC3-AS1 | EMC4 | EMC6 | EMC7 | EMC8 | EMC9 | EMCN | EMD | EME1 | EME2 | EMG1 | EMID1 | EMILIN1 | EMILIN2 | EML1 | EML2 | EML2-AS1 | EML3 | EML4 | EML4-AS1 | EML5 | EML6 | EMP1 | EMP2 | EMP2P1 | EMP3 | EMSLR | EMSY | EMX1 | EMX2 | EMX2OS | EN1 | EN2 | ENAH | ENAM | ENC1 | ENDOD1 | ENDOG | Endogenous Retrovirus group K Env polyprotein (ERVK) | Endogenous retrovirus group K member 25 Pol protein-like, transcript variant X1 | EndoGlyx-1 | Endoplasmic reticulum collagen prolyl 3-hydroxylation complex | Endothelin receptor | Endothelin-Converting Enzymes (ECE) | Endothiapepsin | ENDOU | ENDOV | ENG | ENGASE | ENHO | ENKD1